Advancing novel, small molecule treatments targeting epigenetic mechanisms in tumor and immune cells for the benefit of patients

Constellation Pharmaceuticals is a leader in epigenetics. The company leverages insights from chromatin biology to discover and develop small molecule therapeutics for the treatment of cancer by targeting transcriptional pathways and acquired dependencies in tumor cells and by targeting immune cells to enhance their cancer fighting abilities. In addition to the recent progression of its EZH2 inhibitor, CPI-1205, into the clinic, the company disclosed at the recent ASH convention in Orlando, Fla., that it has observed a number of objective responses in lymphoma patients being treated with its Phase 1 BET protein bromodomain inhibitor, CPI-0610, currently being evaluated in three Phase 1 clinical trials in the U.S. The company’s innovative product discovery engine targets both enzymes that modify the dynamic structure of chromatin (writers and erasers) and other proteins that interact with chromatin (readers) to control gene expression. Restoration of normal gene expression through chromatin modulation by highly selective and specific inhibitors promises to be a powerful approach to the development of important new medicines against a broad range of diseases.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

July 18, 2017
Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer

May 25, 2017
Jigar Raythatha Rejoins Constellation Pharmaceuticals as President and CEO

April 19, 2016
Constellation Pharmaceuticals, Inc. To Present At The Epigenetics: Cancer and Beyond Symposium

Read More News

Associated Team Members

Robert Tepper, M.D.

Neil Exter

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Mark Levin

Keith Dionne, Ph.D.